BRPI0417747A - uso de compostos orgánicos - Google Patents

uso de compostos orgánicos

Info

Publication number
BRPI0417747A
BRPI0417747A BRPI0417747-9A BRPI0417747A BRPI0417747A BR PI0417747 A BRPI0417747 A BR PI0417747A BR PI0417747 A BRPI0417747 A BR PI0417747A BR PI0417747 A BRPI0417747 A BR PI0417747A
Authority
BR
Brazil
Prior art keywords
organic compounds
pharmaceutically acceptable
pitavastatin
statin
medicament
Prior art date
Application number
BRPI0417747-9A
Other languages
English (en)
Inventor
Michele Bortolini
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0417747A publication Critical patent/BRPI0417747A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Quinoline Compounds (AREA)

Abstract

"USO DE COMPOSTOS ORGáNICOS". A presente invenção refere-se ao uso de uma composição farmacêutica consistindo em estatina (especialmente fluvastatina ou pitavastatina) ou um sal farmaceuticamente aceitável da mesma e um veículo farmaceuticamente aceitável para a preparação de um medicamento para a prevenção ou tratamento da síndrome metabólica (ou síndrome X).
BRPI0417747-9A 2003-12-16 2004-12-15 uso de compostos orgánicos BRPI0417747A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52983103P 2003-12-16 2003-12-16
PCT/EP2004/014304 WO2005058310A2 (en) 2003-12-16 2004-12-15 Use of stating for the treatment of metabolic syndrome

Publications (1)

Publication Number Publication Date
BRPI0417747A true BRPI0417747A (pt) 2007-04-10

Family

ID=34700055

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0417747-9A BRPI0417747A (pt) 2003-12-16 2004-12-15 uso de compostos orgánicos

Country Status (11)

Country Link
US (1) US20070275996A1 (pt)
EP (1) EP1699452A2 (pt)
JP (1) JP2007513991A (pt)
KR (1) KR20060124634A (pt)
CN (1) CN1889948A (pt)
AU (1) AU2004298351A1 (pt)
BR (1) BRPI0417747A (pt)
CA (1) CA2546793A1 (pt)
MX (1) MXPA06006831A (pt)
RU (1) RU2006125512A (pt)
WO (1) WO2005058310A2 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080033030A1 (en) * 2006-02-24 2008-02-07 Capua Simona D Fluvastatin sodium pharmaceutical compositions
WO2007111027A1 (ja) * 2006-03-29 2007-10-04 Kowa Co., Ltd. トリグリセリド低下剤及び高インスリン血症改善剤
EP1911441A3 (en) * 2006-10-11 2008-08-06 Lupin Limited Controlled release color stable pharmaceutical dosage form of HMG-COA reductase inhibitors, free of alkalizing or buffering agents
IS8612A (is) * 2007-02-19 2008-08-20 Actavis Group Ptc Ehf. Stöðugar statínlyfjasamsetningar
US8048880B2 (en) 2007-05-03 2011-11-01 Anthera Pharmaceuticals, Inc. Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase A2 (SPLA2) inhibitors and SPLA2 inhibitor combination therapies
RU2373914C1 (ru) * 2008-05-12 2009-11-27 Илья Николаевич Медведев Способ коррекции уровня микровезикул в крови при абдоминальном ожирении
FR2987270A1 (fr) * 2012-02-29 2013-08-30 Agronomique Inst Nat Rech Produit de combinaison pour le traitement du surpoids et/ou l'amelioration de la silhouette

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020089433A (ko) * 2000-04-12 2002-11-29 노파르티스 아게 유기화합물의 조합
AR039090A1 (es) * 2002-03-22 2005-02-09 Novartis Ag Combinacion de compuestos organicos
US20040053842A1 (en) * 2002-07-02 2004-03-18 Pfizer Inc. Methods of treatment with CETP inhibitors and antihypertensive agents
HUP0300990A2 (hu) * 2003-04-15 2005-05-30 SynoSens Kutató és Fejlesztő Kft. Szinergista gyógyszer-kombináció a diabetesz megelőzésére vagy kezelésére
CA2524175C (en) * 2003-04-28 2016-06-14 Sankyo Company Limited Sugar intake-ability enhancer

Also Published As

Publication number Publication date
CN1889948A (zh) 2007-01-03
EP1699452A2 (en) 2006-09-13
WO2005058310A2 (en) 2005-06-30
AU2004298351A1 (en) 2005-06-30
MXPA06006831A (es) 2006-08-23
WO2005058310A3 (en) 2005-08-25
JP2007513991A (ja) 2007-05-31
KR20060124634A (ko) 2006-12-05
RU2006125512A (ru) 2008-01-27
US20070275996A1 (en) 2007-11-29
CA2546793A1 (en) 2005-06-30

Similar Documents

Publication Publication Date Title
ATE339406T1 (de) Chinazoline verbindungen als heilmittel
BR0107147A (pt) Composições farmacêuticas de drogas anti-tuberculosas e processo para as suas preparações
BRPI0515896A (pt) composto ou um sal ou éster farmaceuticamente aceitável do mesmo, método para o tratamento ou profilaxia de um hospedeiro infectado com uma infecção por flavivìrus, pestivìrus ou hepacivìrus, e, composição farmacêutica para o tratamento de um hospedeiro infectado com uma infecção por flavivìrus, pestivìrus ou hepacivìrus
BR0315580A (pt) Derivados de metileno uréia
BRPI0410049A (pt) composto ou um sal ou estereoisÈmero farmaceuticamente aceitável do mesmo, uso de um composto, composição farmacêutica, e, kit farmacêutico
ITRM990338A0 (it) Composizione dietetica o farmaceutica utile per la prevenzione o il trattamento dell'iperossaluria.
WO2004002999A8 (en) Modified 2' and 3' -nucleoside produgs for treating flaviridae infections
LU92496I2 (fr) Combinaison de dapagliflozine ou d'un sel pharmaceutiquement acceptable de celle-ci et de merformineou d'un sel pharmaceutiquement acceptable de cell-ci, telle que protégée par le brevet de base EP1506211 B1
BRPI0507497A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, formulação farmacêutica, uso de um composto, e, métodos para prevenir e/ou tratar distúrbios mediados por receptor de mglur5 e para inibir a ativação de receptores de mglur5
BR0314488A (pt) Composto, composição farmacêutica e métodos de tratamento
BR0010520A (pt) Novos compostos farmaceuticamente ativos
LT2001119A (en) Pharmaceutical formulations comprising intranasal morphine and use thereof
BR0212787A (pt) Composto ou sal farmaceuticamente aceitável do mesmo, métodos de tratamento ou prevenção de doenças e de preparação de um composto, uso de um composto ou sal, e, composição farmacêutica
SE9901573D0 (sv) New compounds
DE60001974D1 (de) Derivate von flavonen, xanthonen und kumarinen
TR199900336T2 (xx) EAA antagonistleri olarak tetrahidrokinolin t�revleri.
BRPI0405657A (pt) Método para o tratamento de insuficiência cardìaca grave e medicamento para o mesmo
EP1785137A4 (en) CURE FOR HYPERLIPIDEMIA
BR0307588A (pt) Composto, inibidor de gsk-3, composição farmacêutica, e, agente terapêutico ou preventivo para uma doença
WO2005117895A8 (en) Compositions comprising meloxicam
BRPI0417747A (pt) uso de compostos orgánicos
DE69931378D1 (de) Chinazolin derivate und therapeutische verwendungen davon
BRPI0508079A (pt) composto ou uma forma cristalina ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, métodos de tratar ou prevenir uma infecção viral com hepatite c em um mamìfero e de inibir replicação de um vìrus da hepatite c
CA2385755A1 (en) Prevention of colorectal cancer
BR0317947A (pt) Inibidores de quinurenina 3-hidroxilase para o tratamento de diabetes

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.